Search academic texts

Information × Registration Number 0220U102622, 0118U003732 , R & D reports Title Develop new methods of combined treatment for patients with breast cancer with an unfavorable prognosis. popup.stage_title Head Smolanka Ivan I, Доктор медичних наук Registration Date 10-04-2020 Organization National Cancer Institute popup.description2  Direct results of treatment of patients with breast cancer with unfavorable prognosis with the use of standard and developed methods of neoadjuvant polychemotherapy with magnetotherm are analyzed. Comparative analysis of the intermediate results indicates a clear advantage of the methods of selective intra-arterial polychemotherapy with magnetotherm compared to standard systemic polychemotherapy. The results of treatment of patients with edematous forms of breast cancer were evaluated according to the developed method, where a selective intra-arterial route of administration of chemotherapeutic drugs in combination with magnetotherm was applied. The advantages of using this method were determined by the number of complete (15.7% in the main vs. 6.9% in the control group) and partial tumor regressions (45.1% in the main vs. 34.0% in the control group), and the amount of process progression ( 5.9% in the main group versus 17% in the control group). The developed technique allowed to perform radical surgery more than half of the patients of the main group due to the high rate of partial tumor regression. The results of treatment of patients with locally advanced breast cancer with the use of system-selective neoadjuvant polychemotherapy using magnetotherm according to the developed method have been evaluated. It is found that the use of the developed method contributes to a significant increase in the objective response of the tumor to treatment (allows to increase by 26.7% the number of cases of complete and partial regression of the primary tumor according to RECIST criteria). Conducting neoadjuvant system-selective polychemotherapy using magnetothermia allows to increase by 26.7% the percentage of organ-saving surgical interventions. The technique of neoadjuvant hormone therapy for patients with IPRHZ of the luminal subtype has been developed, which includes the appointment of aromatase inhibitors for up to 4 months. Product Description popup.authors Ivankova Oksana M Dosenko Iryna V Kostryba Oleksii I Loboda Anton D Lyashenko Andrij O Smolanka Ivan I popup.nrat_date 2020-07-03 Close